TECP
CYTK icon

Trails Edge Capital Partners’s Cytokinetics CYTK Stock Holding History

Trails Edge Capital Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.5M Sell
288,089
-11,911
-4% -$855K 3.9% 11
2026
Q1 		$19.8M Buy
+300,000
New +$19.1M 4.53% 10

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Trails Edge Capital Partners's CYTK Position: Q2 2026 in Review

Trails Edge Capital Partners reduced its Cytokinetics (CYTK) stake by 4% in Q2 2026, selling an estimated $855K and leaving 288,089 shares worth $24.5M. The position accounts for 3.9% of the portfolio, ranked #11.

Trails Edge Capital Partners first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 481 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Trails Edge Capital Partners held 288,089 shares of Cytokinetics worth $24.5M as of Q2 2026.
  • Trails Edge Capital Partners sold 11,911 Cytokinetics shares in Q2 2026, an estimated $855K.
  • Cytokinetics made up 3.9% of Trails Edge Capital Partners's portfolio in Q2 2026, its #11 holding.
  • Trails Edge Capital Partners first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
  • 481 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Trails Edge Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.